They have not been studied clinically in gynecologic malignancies; however, there is preclinical evidence supporting the use of neratinib alone or in combination with olaparib, in HER2 overexpressing uterine serous carcinoma [30,31]. This evidence concerns the gene ERBB2 and endometrial serous adenocarcinoma.